Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim- sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4951-4952

  Köser, Claudio U ^a   Summers, David K ^a   Archer, John A C ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LETTER; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 78049294181     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00876-10     Document Type: Letter

References (17)

1. Abe, C., I. Kobayashi, S. Mitarai, M. Wada, Y. Kawabe, T. Takashima, K. Suzuki, L. H. Sng, S. Wang, H. H. Htay, and H. Ogata. 2008. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J. Clin. Microbiol. 46:2263-2268.
2. Ali, A., Z. Hasan, T. Moatter, M. Tanveer, and R. Hasan. 2009. M. tuberculosis Central Asian Strain 1 MDR isolates have more mutations in rpoB and katG genes compared with other genotypes. Scand. J. Infect. Dis. 41:37-44.
3. Reference deleted.
4. Comas, I., S. Homolka, S. Niemann, and S. Gagneux. 2009. Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS One 4:e7815.
5. Coronel, J., M. Roper, L. Caviedes, and D. Moore. 2008. MODS: a user guide, version 12.1 14082008. Universidad Peruana Cayetano Heredia, Lima, Peru.
6. Date, A., M. Vitoria, R. Granich, M. Banda, M. Fox, and C. Gilks. 2010. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull. W. H. O. 88:253-259.
7. Fleischmann, R. D., D. Alland, J. A. Eisen, L. Carpenter, O. White, J. Peterson, R. DeBoy, R. Dodson, M. Gwinn, D. Haft, E. Hickey, J. F. Kolonay, W. C. Nelson, L. A. Umayam, M. Ermolaeva, S. L. Salzberg, A. Delcher, T. Utterback, J. Weidman, H. Khouri, J. Gill, A. Mikula, W. Bishai, W. R. Jacobs, Jr., J. C. Venter, and C. M. Fraser. 2002. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J. Bacteriol. 184:5479-5490.
8. Forgacs, P., N. Wengenack, L. Hall, S. Zimmerman, M. Silverman, and G. Roberts. 2009. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53:4789-4793.
9. Harries, A., R. Zachariah, E. Corbett, S. Lawn, E. Santos-Filho, R. Chimzizi, M. Harrington, D. Maher, B. Williams, and K. De Cock. 2010. The HIV-associated tuberculosis epidemic-when will we act? Lancet 375:1906-1919.
10. Huovinen, P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32:1608-1614.
11. Larsen, M., C. Vilchèze, L. Kremer, G. Besra, L. Parsons, M. Salfinger, L. Heifets, M. Hazbon, D. Alland, J. Sacchettini, and W. J. Jacobs. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
12. Moore, D., C. Evans, R. Gilman, L. Caviedes, J. Coronel, A. Vivar, E. Sanchez, Y. Piñedo, J. Saravia, C. Salazar, R. Oberhelman, M. Hollm-Delgado, D. LaChira, A. Escombe, and J. Friedland. 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355:1539-1550.
13. Mwenya, D., B. Charalambous, P. Phillips, J. Mwansa, S. Batt, A. Nunn, S. Walker, D. Gibb, and S. Gillespie. 2010. Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob. Agents Chemother. 54:3756-3762.
14. Ong, W., A. Sievers, and D. Leslie. 2010. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob. Agents Chemother. 54:2748. (Author's reply, 2748-2749.)
15. Suling, W., R. Reynolds, E. Barrow, L. Wilson, J. Piper, and W. Barrow. 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 42:811-815.
16. Wang, F., P. Jain, G. Gulten, Z. Liu, Y. Feng, K. Ganesula, A. Motiwala, T. Ioerger, D. Alland, C. Vilchèze, W. J. Jacobs, and J. Sacchettini. 2010. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob. Agents Chemother. 54:3776-3782.
17. Young, L. 2009. Reconsidering some approved antimicrobial agents for tuberculosis. Antimicrob. Agents Chemother. 53:4577-4579.